Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European community systemic vasculitis clinical trials study group

Mayo Clinic Proceedings

Volumn 72, Issue 8, 1997, Pages 737-747

  Jayne, David R W ^a   Rasmussen, Niels ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; EUROPE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INTERNATIONAL COOPERATION; MULTICENTER STUDY; REVIEW; VASCULITIS;

ADRENAL CORTEX HORMONES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; METHOTREXATE; METHYLPREDNISOLONE; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 0031201034     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(11)63594-5     Document Type: Review

References (63)

1. Gross WL. Antineutrophil cytoplasmic autoantibody testing in vasculitides. Rheum Dis Clin North Am 1995 Nov;21:987-1011
2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192
3. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross W, et al (EEC/BCR Group for ANCA Assay Standardization). The value of indirect immunofluorescence and solid phase techniques for ANCA detection: a report on the first phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1993; 159:1-16
4. Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989;! 11:28-40
5. Kettritz R, Yang JJ, Kinjoh K, Jennette JC, Falk RJ. Animal models in ANCA-vasculitis. Clin Exp Immunol 1995;101(Suppl 1):12-15
6. Scott DGI, Watts RA. Classification and epidemiology of systemic vasculitis [editorial]. BrJRheumatol 1994;33:897899
7. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. ClinNephrol 1992;37:219-228
8. Andrews M, Edmunds M, Campbell A, Walls J, Feehally J. Systemic vasculitis in the 1980s-is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 1990;24:284-288
9. Rasmussen N, Jayne DRW, Abramowicz D, Andrassy K, Bacon PA, Cohen Tervaert JW, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995;101(Suppl l):29-34
10. Wegener F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat Allg Pathol 1939; 102:36-68
11. Godman GC, Churg J. Wegener's granulomatosis: pathology and review of the literature. Arch Pathol 1954;58:533553
12. Wiik A, Rasmussen N, Wieslander J. Methods to detect autoantibodies to neutrophilic granulocytes. In: van Venrooij WJ, Maini RN, editors. Manual of Biological Markers of Disease. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1993. pp 1-14
13. Devaney KO, Travis WD, Huffman G, Leavitt R, Lebovics R, Fauci AS. Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14:555-564
14. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. QJMed 1948;17:175-202
15. Savage COS. Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. QJMed 1985;56:467-483
16. Adu D, Howie AJ, Scott DGI, Bacon PA, McGonigle RJS, Michael J. Polyarteritis and the kidney. Q J Med 1987:62:221-237
17. Croker BP, Lee T, Gunnells JC. Clinical and pathologic features of polyarteritis nodosa and its renal-limited variant: primary crescentic and necrotizing glomerulonephritis. Hum Pathol 1987; 18:38-44
18. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum 1994:37:919924
19. Luqmani RA, Bacon PA, Moots RJ, Janssen B A, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87:671-678
20. Banbury P, Exley AR, Moots RJ, Luqmani R, Kitas G, Bacon PA. The vasculitis damage index (VDI) [abstract]. Clin Exp Immunol 1995;101(Suppl 1):42
21. Luqmani RA, Kitas GD, Exley A, Moots RJ, Landais P, Bacon PA. et al. The validation of a vasculitis integrated total assessment log (VITAL) [abstract]. Clin Exp Immunol 1995;101(Suppl 1):45
22. Ware JE Jr. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
23. Exley AR, Moots RJ, Carruthers D, Bacon PA. Short-form 36 in vasculitis [abstract]. Clin Exp Immunol 1995; lOKSuppl 1):63
24. Bacon PA, Moots RJ, Exley A, Luqmani R, Rasmussen N. VITAL assessment of vasculitis. Clin Exp Rheumatol 1995:13:275-278
25. Fauci AS, Katz P, Haynes BF. Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N EnglJMed 1979;301:235-238
26. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85
27. Huffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;! 16:488-498
28. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989:32:45-53
29. Dale DC. Fauci AS, Wolff SM. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener's granulomatosis. Arthritis Rheum 1973:16:657-664
30. Neild GH. Infectious complications in the management of systemic vasculitis and rapidly progressive glomerulonephritis. APMISSuppl 1990:19:56-60
31. Capizzi RL, Bertino JR. Methotrexate therapy of Wegener's granulomatosis. Ann Intern Med 1971;74:74-79
32. Huffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-1329
33. Sneller MC, Huffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-613
34. Gaskin G, Pusey CD. Systemic vasculitis. In: Cameron S, Davison AM, Grünfeld J-P, Kerr D, Ritz E, editors. Oxford Textbook of Clinical Nephrology. Voll. Oxford (England): Oxford University Press; 1992. pp 612-636
35. Bouroncle BA, Smith EJ, Cuppage FE. Treatment of Wegener's granulomatosis with Imuran. Am J Med 1967; 42:314-318
36. Norton WL, Suki W, Strunk S. Combined corticosteroid and azathioprine therapy: in two patients with Wegener's granulomatosis. Arch Intern Med 1968; 121:554-560
37. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127-133
38. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976;1:711715
39. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757763
40. Levy JB, Winearls CG. Rapidly progressive glomerulonephritis: what should be first-line therapy? Nephron 1994;67:402-407
41. Bolton WK, Sturgill BC. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989;9:368-375
42. Gaskin G, Savage COS, Ryan JJ, Jones S, Rees AJ, Lockwood CM, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-694
43. Hagen EC, de Keizer RJW, Andrassy K, van Boven WPL, Bruijn JA, van Es LA, et al. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995;43:351-359
44. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341:16201622
45. Cohen Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-2465
46. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:1217
47. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-347
48. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-1231
49. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-1139
50. Richter C, Schnabel A, Csernok E, De Groot K, ReinholdKeller E, Gross WL. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7
51. Moudgil A, Tuso P, Kamil E, Koyyana R, Jordan SC. Treatment of Wegener's granulomatosis (WG) with pooled intravenous gammaglobulin (IVIG) [abstract]. J Am Soc Nephrol 1991;2:600
52. Rossi F, Jayne DRW, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991;83:298-303
53. Ronda N, Kaveri SV, Kazatchkine MD. Treatment of autoimmune diseases with normal immunoglobulin through manipulation of the idiotypic network. Clin Exp Immunol 1993;93(Suppl 1): 14-15
54. DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum 1988;31:1068-1074
55. Stegeman ÇA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM (Dutch Co-trimoxazole Wegener Study Group). Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl JMed 1996;335:16-20
56. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995;25:228-234
57. Harrison HL, Linshaw MA, Lindsley CB, Cuppage FE. Bolus corticosteroids and cyclophosphamide for initial treatment of Wegener's granulomatosis. JAMA 1980;244:15991600
58. Fort JG, Abruzzo JL. Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum 1988;31:1194-1198
59. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403-410
60. Cupps TR. Cyclophosphamide: to pulse or not to pulse? [editorial]. Am J Med 1990:89:399-402
61. Falk RJ, Hogan S, Carey TS, Jennette JC, Glomerular Disease Collaborative Network. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;! 13:656663
62. Guillevin L, Lhote F, Jarrousse B, Cohen P, Jacquot C, Lesavre P, et al. Treatment of severe Wegener's granulomatosis (WG): a prospective trial in 50 patients comparing prednisone (CS), pulse cyclophosphamide (CY) versus CS and oral C Y [abstract]. Clin Exp Immunol 1995; 101 (Suppl 1):43
63. Cohen J, Pinching AJ, Rees AJ, Peters DK. Infection and immunosuppression: a study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 1982;51:1-15